GIC
VRTX icon

Generali Investments CEE’s Vertex Pharmaceuticals VRTX Stock Holding History

Generali Investments CEE’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.26M Hold
10,599
– – 0.25% 109
2026
Q1 		$4.73M Buy
10,599
+108
+1% +$50.4K 0.25% 117
2025
Q4 		$4.76M Hold
10,491
– – 0.34% 92
2025
Q3 		$4.11M Hold
10,491
– – 0.31% 102
2025
Q2 		$4.67M Sell
10,491
-539
-5% -$248K 0.38% 81
2025
Q1 		$5.35M Hold
11,030
– – 0.5% 57
2024
Q4 		$4.44M Buy
+11,030
New +$5.11M 0.46% 65

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
GIA
Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return
MLL
Moody Lynn & Lieberson Boston, Massachusetts $1.9B AUM 27.82% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.87B AUM 24.22% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

Generali Investments CEE's VRTX Position: Q2 2026 in Review

Generali Investments CEE held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 10,599 shares worth $5.26M. The position accounts for 0.25% of the portfolio, ranked #109.

Generali Investments CEE first reported a position in VRTX in Q4 2024 and has held it in 7 quarters since. The position peaked at $5.35M in Q1 2025. 299 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Generali Investments CEE held 10,599 shares of Vertex Pharmaceuticals worth $5.26M as of Q2 2026.
  • Generali Investments CEE left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
  • Vertex Pharmaceuticals made up 0.25% of Generali Investments CEE's portfolio in Q2 2026, its #109 holding.
  • Generali Investments CEE first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • Generali Investments CEE's Vertex Pharmaceuticals position peaked at $5.35M in Q1 2025.
  • 299 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Generali Investments CEE's 13F filing for Q2 2026, filed 13 Jul 2026.